Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity: 2016-2024

Historic Liabilities and Shareholders Equity for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $220.7 million.

  • Akebia Therapeutics' Liabilities and Shareholders Equity rose 75.80% to $364.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 38.69%. This contributed to the annual value of $220.7 million for FY2024, which is 8.70% down from last year.
  • Akebia Therapeutics' Liabilities and Shareholders Equity amounted to $220.7 million in FY2024, which was down 8.70% from $241.7 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $644.1 million for FY2020, and its period low was $220.7 million during FY2024.
  • In the last 3 years, Akebia Therapeutics' Liabilities and Shareholders Equity had a median value of $241.7 million in 2023 and averaged $272.8 million.
  • Data for Akebia Therapeutics' Liabilities and Shareholders Equity shows a maximum YoY tumbled of 32.74% (in 2022) over the last 5 years.
  • Over the past 5 years, Akebia Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $644.1 million in 2020, then decreased by 17.82% to $529.3 million in 2021, then plummeted by 32.74% to $356.1 million in 2022, then tumbled by 32.12% to $241.7 million in 2023, then fell by 8.70% to $220.7 million in 2024.